Navigation Links
Egenix, Inc. Announces New Director, John Reid
Date:11/14/2012

MILLBROOK, N.Y., Nov. 14, 2012 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of John Reid to its Board of Directors. John Reid retired from Colgate Palmolive as Chief Technological Officer, accountable for Global R&D, IT and the Supply Chain.  Prior to that position he had developed Colgate's first corporate and divisional Strategic Plans before heading subsidiaries in Greece, the UK and the South Pacific, out of Australia.  Earlier he helped write the first corporate and divisional Strategic Plans at Pfizer, before taking operational accountabilities in India and Bangladesh. Dr. Reid served on the Boards of Readers Digest and Minerals Technologies and taught "Practically Global" as an Adjunct Professor at NYU Stern. He has served on several not for profit Boards and is presently President of American Friends of Maungatautari.  Reid was educated in New Zealand and took his D.Phil at Oxford, where he was a Rhodes Scholar and played rugby for the University against the New Zealand All Blacks. Dr. Reid will be a significant addition to the Egenix Board.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an  attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. For more information please visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Egenix, Inc. Announces New Director
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, a ... and seed provider, and Arcadia (Arcadia Biosciences, ... develops and commercializes agricultural productivity traits and nutritional products, today announced ... biotechnology product developed in China to ... trials. ...
(Date:2/22/2017)... PHOENIX and SAN DIEGO ... Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion ... universal donor stem cell product through establishment of ... initiated research activities at the San Diego BioLabs ... Companies, Boehringer Ingelheim, Novartis, and Sanofi. ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... healthcare organizations to build connected digital health applications, announced a partnership with Redox, ... users to seamlessly connect to many clinical systems while keeping data secure in ...
(Date:2/21/2017)... , ... February 21, 2017 , ... The medical potential ... their use, in multiple areas of medicine, due to their differentiating characteristics. Stem cells ... they have the ability to be induced to become tissue or organic-specific cells with ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
Breaking Biology News(10 mins):